Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “PLATINUM 191”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

Nuclear Data Sheets for A = 191

The present revision of the nuclear structure properties for the nuclides belonging to the A = 191 mass chain contains many improvements, corrections and additions to the material presented in previous evaluations (1995Br38, Nucl. Data Sheets 74, 611 (1995)). Besides updating many values, and including supplementary data for already known levels, transitions and level schemes, the most noteworthy modifications with respect to the prior evaluation are the first significant level schemes for {sup 191}Pb, {sup 191}Bi, and {sup 191}Po, showing many levels and transitions, mostly derived from (HI,xn{gamma}) work. The first reports for {sup 191}At and {sup 191}W and the observation of linking transitions from superdeformed levels to normal deformed levels in {sup 191}Hg were also included. Most of decay data sets contain many discrepant data; in some cases, normalization is tentative.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

SU-F-I-56: High-Precision Gamma-Ray Analysis of Medical Isotopes

Purpose: Advanced, time-resolved, Compton-suppressed gamma-ray spectroscopy with germanium detectors is implemented for assaying medical isotopes to study the radioactive decay process leading to a more accurate appraisal of the received dose and treatment planning. Lowell’s Array for Radiological Assay (LARA), a detector array that is comprised of six Compton-suppressed high-purity germanium detectors, is currently under development at UMass-Lowell which combines Compton-suppression and time-and-angle correlations to allow for highly efficient and highly sensitive measurements. Methods: Two isotopes produced Brookhaven Linac Isotope Producer (BLIP) were investigated. {sup 82}Sr which is the parent isotope for producing {sup 82}Rb is often used in cardiac PET. {sup 82}Sr gamma-ray spectrum is dominated by the 511keV photons from positron annihilation which prevent precise measurement of co-produced contaminant isotopes. A second project was to investigate the production of platinum isotopes. Natural platinum was bombarded with protons from 53MeV to 200MeV. The resulting spectrum was complicated due to the large number of stable platinum isotopes in the target, the variety of open reaction channels (p,xn), (p,pxn), (p,axn). Results: By using face-to-face NaI(Tl) counters 90-degrees to the Compton-suppressed germaniums to detect the 511keV photons, a much cleaner and more sensitive measurement of {sup 85}Sr and other contaminants was obtained. For the platinum target, we identified the production of {sup 188–189–191–195}Pt, {sup 191–192–193–194–195–196}Au and {sup 186–188–189–190–192–194–189–190–192–194}Ir. For example, at the lower energies (53 and 65MeV), we measured {sup 191}Pt production cross-sections of 144mb and 157mb. Considerable care was needed in following the process of dissolving and diluting the samples to get consistent results. The new LARA array will help us better ascertain the absolute efficiency of the counting system and more reliable production cross-sections. Conclusion: Modern HPGe spectroscopic techniques provide enhanced sensitivity, promising precise quantification of the quality of radioisotopes used in medical physics. Using new decay information may have non-trivial impact on treatment planning and dose-assessment.

07 ISOTOPE AND RADIATION SOURCES↗

Nuclear Data Sheets for A = 187

Evaluated spectroscopic data and level schemes from radioactive decay and nuclear reaction studies are presented for {sup 187}Hf, {sup 187}Ta, {sup 187}W, {sup 187}Re, {sup 187}Os, {sup 187}Ir, {sup 187}Pt, {sup 187}Au, {sup 187}Hg, {sup 187}Tl, {sup 187}Pb, {sup 187}Bi, and {sup 187}Po. This evaluation for A = 187 supersedes the earlier one by R.B. Firestone (1991Fi02) published in Nuclear Data Sheets 62, 159 (1991) and the {sup 187}Tl evaluation by C.M. Baglin (1999Ba24) published in Nuclear Data Sheets 86, 487 (1999). Highlights of this publication are the following: This evaluation includes first identifications of {sup 187}Hf, {sup 187}Ta (1999Be63, 2000PoZY) and {sup 187}Po (2006An11) nuclides. A B(E2){up_arrow} = 0.080 12 was determined by 1967Bi10 for the 9/2+ state at 845 keV in {sup 187}Re Coulomb Excitation. Using this B(E2) value and the adopted 845{gamma} ray properties, a T{sub 1/2}=54 fs 34 can be deduced for the 845 keV level of {sup 187}Re. This T{sub 1/2} yields a large B(E2)(W.u.){approx}1.3x105 for the 263{gamma} (depopulating the same level) indicating either substantial unobserved feeding or incorrect g-ray branching intensities of this level. The decay of g.s. and isomer of {sup 187}Tl are poorly known (please see {sup 187}Tl {epsilon} decay (51 s+15.60 s)). Based on {sup 191}Po {alpha} decay studies, 2002An19 establishes a {sup 187}Pb isomeric level energy at 2(15) keV and assigns J{pi}=13/2+ for the {sup 187}Pb g.s. and J{pi}=3/2- for the isomeric state (inverse of the systematics of odd-mass Pb nuclei in this region). From {sup 187}Pb and {sup 187}Pb{sup m} mass measurements, 2005We11 determined the isomeric level energy at 33(13) keV.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Mass tensor in the Bohr Hamiltonian from the nondiagonal energy weighted sum rules

Relations are derived in the framework of the Bohr Hamiltonian that express the matrix elements of the deformation-dependent components of the mass tensor through the experimental data on the energies and the E2 transitions relating the low-lying collective states. These relations extend the previously obtained results for the intrinsic mass coefficients of the well-deformed axially symmetric nuclei on nuclei of arbitrary shape. The expression for the mass tensor is suggested, which is sufficient to satisfy the existing experimental data on the energy weighted sum rules for the E2 transitions for the low-lying collective quadrupole excitations. The mass tensor is determined for {sup 106,108}Pd, {sup 108-112}Cd, {sup 134}Ba, {sup 150}Nd, {sup 150-154}Sm, {sup 154-160}Gd, {sup 164}Dy, {sup 172}Yb, {sup 178}Hf, {sup 188-192}Os, and {sup 194-196}Pt.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Cisplatin Pharmacokinetics in Nontumoral Pig Liver Treated With Intravenous or Transarterial Hepatic Chemoembolization

Purpose: To evaluate cisplatin (CDDP) pharmacokinetics after its intravenous (IV) or intrahepatic arterial administration (IHA) in healthy pigs with or without embolization by absorbable gelatine. Material and Methods: We analysed plasmatic and hepatic drug concentration in four groups of six mini-pigs each according to the modality of administration of CDDP (1 mg/kg): IV, IHA, IHA with partial embolization using absorbable gelatine (IHA-Pe), and IHA with complete embolization (IHA-Te). Unbounded plasmatic and hepatic platinum concentrations were measured. Concentration and pharmacokinetics parameters were compared using analysis of variance. Results: For all groups, there was a rapid and biexponential decrease in free platinum concentration. Plasmatic terminal half-life (T{sub 1/2}) was significantly decreased after embolization at 191, 178, 42, and 41 min after IV, IHA, IHA-Pe, and IHA-Te administration, respectively. Maximal plasmatic concentration and systemic exposure to CDDP (AUC{sub 24}) values were significantly decreased after embolization (C{sub max}p = 0.0075; AUC{sub 24}p = 0.0053). Hepatic CDDP concentration rapidly peaked and then decreased progressively. After 24 h, the residual concentration represented 45, 47, 60, and 63 % of C{sub max}, respectively, after IV, IHA, IHA-Pe, and IHA-Te. Hepatic T{sub 1/2} and AUC{sub {infinity}} values were increased after embolization, but the differences were not statistically significant. Conclusion: This preliminary study confirms the feasibility of a pig model to study systemic and hepatic CDDP pharmacokinetics. Systemic exposure is lower after embolization, which could minimize systemic toxicity. Hepatic T{sub 1/2} elimination and hepatic exposition values are increased with IHA compared with IV administration.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Proton- and deuteron-induced cross sections on natural platinum

Light-ion irradiations on natural platinum were performed to measure gold-radioisotope cross sections and isotope ratios, as well as to produce a carrier-free final product. Experimental cross sections are compared to TENDL-2023. There is good agreement with this work's results and other published literature values. In conclusion, several novel cross sections were determined including 190 Au, 191 Au, 199 Pt and several independent cross sections.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Trithiol ligand provides tumor-targeting 191 Pt-complexes with high molar activity and promising in vivo properties

The Auger electron-emitting radionuclide 191 Pt is a promising candidate for radiopharmaceutical therapy. Herein, we explored novel labeling methods for 191 Pt using thiol-containing ligands to improve the in vivo stability and targeting ability of 191 Pt-labeled complexes. We synthesized dithiol-containing N 2 S 2 and NS 2 ligands, and a trithiol ligand, and then compared their radiochemical reactivity with 191 Pt. [ 191 Pt]Pt-trithiol was synthesized and its biodistribution was evaluated in mice and compared with free 191 Pt. Finally, a 191 Pt-trithiol complex targeting prostate-specific membrane antigen (PSMA): [ 191 Pt]Pt-trithiol-PSMA was developed and evaluated in mice bearing tumor xenografts and compared with a 191 Pt-complex labeled via monothiol-containing Cys ([ 191 Pt]Pt-Cys-PSMA). A comparison of N 2 S 2 , NS 2 , and trithiol showed that the trithiol ligand is the best for producing 191 Pt-labeled compounds in high yield and as a single peak in preparative HPLC. Notably, the trithiol ligand made 191 Pt-labeled compounds and precursors separatable, achieving 191 Pt-labeled products with a high molar activity: 200–400 mCi/μmol (7.4–14.8 GBq/μmol) at EOS. Additionally, [ 191 Pt]Pt-trithiol and [ 191 Pt]Pt-trithiol-PSMA were stable in vivo with rapid clearance compared with free 191 Pt and [ 191 Pt]Pt-Cys-PSMA. [ 191 Pt]Pt-trithiol-PSMA resulted in a low uptake in most normal organs and a high uptake in the kidneys and prostate cancer with PSMA expression. Furthermore, this study demonstrated that a labeling method with trithiol for Pt radionuclides achieves 191 Pt-labeled products with high molar activity. 191 Pt-trithiol-PSMA showed promising in vivo stability and tumor-targeting specificity, which should facilitate the pharmaceutical development of Pt radionuclides for radiopharmaceutical therapy, especially Auger electron cancer therapy.

Auger emitters↗

Semiphenomenological approximation of the sums of experimental radiative strength functions for dipole gamma transitions of energy E{sub {gamma}}below the neutron binding energy B{sub n} for mass numbers in the range 40 {<=} A {<=} 200

The sums of radiative strength functions for primary dipole gamma transitions, k(E1) + k(M1), are approximated to a high precision by a superposition of two functional dependences in the energy range 0.5 < E{sub 1} < B{sub n} - 0.5 MeV for the {sup 40}K, {sup 60}Co, {sup 71,74}Ge, {sup 80}Br, {sup 114}Cd, {sup 118}Sn, {sup 124,125}Te, {sup 128}I, {sup 137,138,139}Ba, {sup 140}La, {sup 150}Sm, {sup 156,158}Gd, {sup 160}Tb, {sup 163,164,165}Dy, {sup 166}Ho, {sup 168}Er, {sup 170}Tm, {sup 174}Yb, {sup 176,177}Lu, {sup 181}Hf, {sup 182}Ta, {sup 183,184,185,187}W, {sup 188,190,191,193}Os, {sup 192}Ir, {sup 196}Pt, {sup 198}Au, and {sup 200}Hg nuclei. It is shown that, in any nuclei, radiative strength functions are a dynamical quantity and that the values of k(E1) + k(M1) for specific energies of gamma transitions and specific nuclei are determined by the structure of decaying and excited levels, at least up to the neutron binding energy B{sub n}.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗